AHA Statement Reviews Primary and Secondary Raynaud Phenomenon

An American Heart Association scientific statement published in Circulation reviews evidence on primary and secondary Raynaud phenomenon, a disorder characterized by episodic vasospasm in small arteries and arterioles of the extremities. Attacks often follow environmental triggers or emotional stress and produce skin color changes associated with reduced perfusion and subsequent reperfusion. The statement addresses quality of life measures, medical management, botulinum toxin therapy, and surgery for severe cases.

Although the two forms share symptoms, they differ in pathogenesis, severity, duration, and complications. Primary Raynaud phenomenon usually affects women in the second decade of life and typically has a benign course. Secondary Raynaud phenomenon generally develops later in association with an underlying systemic condition and, in severe cases, can cause digital ischemia or tissue loss.

Management includes lifestyle modifications and pharmacologic treatment. The statement emphasizes treating the underlying disease in secondary Raynaud phenomenon to improve vascular symptoms and prevent complications. Emerging evidence suggests advanced imaging may help detect secondary disease earlier. However, clinical trials evaluating treatment options remain scarce, and uncertainties persist regarding pathophysiology, management, and quality of life. The available abstract provides no quantitative treatment effects or detailed recommendations; the full statement was not available for this update.